Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome
… ProQR Announces Amendment to Convertible Debt Financing … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) (“ProQR”), a company dedicated to changing lives through the … said Smital Shah, Chief Business and Financial Officer of ProQR. “If fully drawn down, this facility extends our cash …
… ProQR Highlights Upcoming Presentation at 20th Annual Meeting … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … Platenburg, co-founder and Chief Scientific Officer at ProQR, will present on Tuesday, October 8 at 10:15 am ET …
… ProQR Highlights Upcoming Presentations on Axiomer™ RNA … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … Platenburg, Chief Scientific Officer and co-founder, ProQR. “We continue to be impressed by the robust editing …
… ProQR Strengthens Scientific Advisory Board with Leaders in … said Daniel A. de Boer, Chief Executive Officer of ProQR. “These individuals bring important scientific, … for patients living with Inherited Retinal Diseases.” ProQR’s SAB is comprised of: James Shannon, MD , Chair of the …
… ProQR to Present Data on its Axiomer® RNA Editing Technology … & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …
… ProQR Announces Virtual Presentation at American Association … & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR ), a company dedicated … and Strabismus (AAPOS) held April 9-11, 2021. ProQR’s presentation Presentation title: A different type of …
… ProQR Announces Presentations at the European CF Conference … will be accessible from the Investor Relations section of ProQR’s website ( www.proqr.com ) under Events and Presentations . The archived …